Inventor
YIN QUN
US30 patents
⚠️ This page may combine multiple inventors who share the name “YIN QUN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
AFFYMAX INC
7 patentsUS7084245B2Aug 1, 2006
Peptides that bind to the erythropoietin receptor
AFFYMAX INC181 citations97
US7528104B2May 5, 2009
Peptides that bind to the erythropoietin receptor
AFFYMAX INC15 citations83
US7109299B1Sep 19, 2006
Peptides and compounds that bind to the IL-5 receptor
AFFYMAX INC12 citations82
US7414105B2Aug 19, 2008
Peptides that bind to the erythropoietin receptor
AFFYMAX INC6 citations72
US7855175B2Dec 21, 2010
Peptides that bind to the erythropoietin receptor
AFFYMAX INC3 citations62
US7919118B2Apr 5, 2011
Spacer moiety for poly (ethylene glycol) modified peptide based compounds
AFFYMAX INC1 citations51
US7482433B2Jan 27, 2009
Peptides and compounds that bind to the IL-5 receptor
AFFYMAX INC0 citations50
KAI PHARMACEUTICALS INC
6 patentsUS8377880B2Feb 19, 2013
Therapeutic agents for reducing parathyroid hormone levels
KAI PHARMACEUTICALS INC9 citations91
US9701712B2Jul 11, 2017
Therapeutic agents for reducing parathyroid hormone levels
KAI PHARMACEUTICALS INC4 citations82
US9278995B2Mar 8, 2016
Therapeutic agents for reducing parathyroid hormone levels
KAI PHARMACEUTICALS INC4 citations82
US9567370B2Feb 14, 2017
Therapeutic agents for reducing parathyroid hormone levels
KAI PHARMACEUTICALS INC2 citations71
US8017583B2Sep 13, 2011
Methods of use of epsilon inhibitor compounds for the attenuation of pain
KAI PHARMACEUTICALS INC2 citations62
US10280198B2May 7, 2019
Therapeutic agents for reducing parathyroid hormone levels
KAI PHARMACEUTICALS INC0 citations50
SUTRO BIOPHARMA INC
4 patentsUS9840493B2Dec 12, 2017
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
SUTRO BIOPHARMA INC24 citations94
US10442789B2Oct 15, 2019
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
SUTRO BIOPHARMA INC4 citations73
US11866515B2Jan 9, 2024
Hemiasterlin derivatives for conjugation and therapy
SUTRO BIOPHARMA INC0 citations60
US10844090B2Nov 24, 2020
Hemiasterlin derivatives for conjugation and therapy
SUTRO BIOPHARMA INC1 citations60
AMGEN INC
4 patentsUS10344765B2Jul 9, 2019
Stable liquid formulation of AMG 416 (etelcalcetide)
AMGEN INC2 citations73
US9820938B2Nov 21, 2017
Stable liquid formulation of AMG 416 (etelcalcetide)
AMGEN INC3 citations73
US11959486B2Apr 16, 2024
Stable liquid formulation of AMG 416 (etelcalcetide)
AMGEN INC0 citations62
US11162500B2Nov 2, 2021
Stable liquid formulation of AMG 416 (etelcalcetide)
AMGEN INC0 citations62
GLAXO GROUP LTD
3 patentsUS6251864B1Jun 26, 2001
Peptides and compounds that bind to a receptor
GLAXO GROUP LTD146 citations98
US5869451AFeb 9, 1999
Peptides and compounds that bind to a receptor
GLAXO GROUP LTD206 citations97
US6506362B1Jan 14, 2003
Labeled compounds that bind to a thrombopoietin receptor
GLAXO GROUP LTD39 citations92
HOLMES CHRISTOPHER P
3 patentsUS8729030B2May 20, 2014
Peptides that bind to the erythropoietin receptor
HOLMES CHRISTOPHER P1 citations61
US8304391B2Nov 6, 2012
Peptides that bind to the erythropoietin receptor
HOLMES CHRISTOPHER P2 citations60
US8592365B2Nov 26, 2013
Spacer moiety for poly(ethylene glycol) modified peptide based compounds
HOLMES CHRISTOPHER P0 citations50